Close

Marinus Pharma (MRNS) Announes Positive Preliminary Data from CDKL5 Patients Enrolled in Ongoing Phase 2 Open-Label Study Evaluating CNS-Selective GABAA Modulator, Ganaxolone

January 23, 2017 7:36 AM EST Send to a Friend
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), today announced positive preliminary data from the initial CDKL5 patients enrolled in its ongoing Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login